144 related articles for article (PubMed ID: 11318774)
1. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol.
Fowler SJ; Lipworth BJ
Br J Clin Pharmacol; 2001 Apr; 51(4):359-62. PubMed ID: 11318774
[TBL] [Abstract][Full Text] [Related]
2. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.
Lipworth BJ; Clark DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):160-3. PubMed ID: 9491830
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.
Newnham DM; McDevitt DG; Lipworth BJ
Br J Clin Pharmacol; 1993 Nov; 36(5):445-50. PubMed ID: 12959292
[TBL] [Abstract][Full Text] [Related]
4. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices.
Lipworth BJ; Clark DJ
Eur J Clin Pharmacol; 1997; 53(1):47-9. PubMed ID: 9349929
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Lipworth BJ; Clark DJ; Koch P; Arbeeny C
Thorax; 1997 Oct; 52(10):849-52. PubMed ID: 9404370
[TBL] [Abstract][Full Text] [Related]
6. Effects of airway calibre on lung delivery of nebulised salbutamol.
Lipworth BJ; Clark DJ
Thorax; 1997 Dec; 52(12):1036-9. PubMed ID: 9516895
[TBL] [Abstract][Full Text] [Related]
7. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27.
Lee DK; Bates CE; Lipworth BJ
Br J Clin Pharmacol; 2004 Jan; 57(1):100-4. PubMed ID: 14678347
[TBL] [Abstract][Full Text] [Related]
8. Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease.
Yang CT; Lin HC; Lin MC; Wang CH; Lee CH; Kuo HP
Eur J Clin Pharmacol; 1996; 49(5):341-5. PubMed ID: 8866625
[TBL] [Abstract][Full Text] [Related]
9. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.
Clark DJ; Lipworth BJ
Thorax; 1996 Oct; 51(10):981-4. PubMed ID: 8977596
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of levosalbutamol: what are the clinical implications?
Boulton DW; Fawcett JP
Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
[TBL] [Abstract][Full Text] [Related]
11. Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol.
Tan KS; McFarlane LC; Lipworth BJ
Chest; 1998 Jan; 113(1):34-41. PubMed ID: 9440565
[TBL] [Abstract][Full Text] [Related]
12. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
Smyth ET; Pavord ID; Wong CS; Wisniewski AF; Williams J; Tattersfield AE
BMJ; 1993 Feb; 306(6877):543-5. PubMed ID: 8096416
[TBL] [Abstract][Full Text] [Related]
13. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.
Lipworth BJ; Clark DJ
Br J Clin Pharmacol; 1998 Jul; 46(1):45-8. PubMed ID: 9690948
[TBL] [Abstract][Full Text] [Related]
14. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.
Lipworth BJ; Brown RA; McDevitt DG
Br J Clin Pharmacol; 1989 Jul; 28(1):95-102. PubMed ID: 2570601
[TBL] [Abstract][Full Text] [Related]
15. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.
Lipworth BJ; McDevitt DG
Eur J Clin Pharmacol; 1989; 36(3):239-45. PubMed ID: 2545455
[TBL] [Abstract][Full Text] [Related]
16. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
Lipworth BJ; Struthers AD; McDevitt DG
Am Rev Respir Dis; 1989 Sep; 140(3):586-92. PubMed ID: 2782734
[TBL] [Abstract][Full Text] [Related]
17. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
Bennett JA; Tattersfield AE
Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
[TBL] [Abstract][Full Text] [Related]
18. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.
Scheinin M; Koulu M; Laurikainen E; Allonen H
Br J Clin Pharmacol; 1987 Nov; 24(5):645-53. PubMed ID: 2829953
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.
Lipworth BJ; Clark RA; Dhillon DP; Moreland TA; Struthers AD; Clark GA; McDevitt DG
Eur J Clin Pharmacol; 1989; 37(6):567-71. PubMed ID: 2693116
[TBL] [Abstract][Full Text] [Related]
20. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe?
Mandelberg A; Krupnik Z; Houri S; Smetana S; Gilad E; Matas Z; Priel IE
Chest; 1999 Mar; 115(3):617-22. PubMed ID: 10084465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
